Zoetis Inc.
- Last sale
- Nov 12, 2026 · +0.48%
- Market cap
- $33.71B
- 406.32M shares
- Filings
- 1,062
Q3 2026+2.3% FY25 yoy
Q3 2026+7.5% FY25 yoy
—
—
—Q3 2026derived−0.7% FY25 yoy
Q3 2026+10.1% FY25 yoy
Q3 2026+23.3% FY25 yoy
- $33.71B
- 13.4×
- 3.6×
- 10.2×
- 6.63%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $9,467,000,000 | reported | |
| FY 2024 | 2024-12-31 | $9,256,000,000 | reported | |
| FY 2023 | 2023-12-31 | $8,544,000,000 | reported | |
| FY 2022 | 2022-12-31 | $8,080,000,000 | reported | |
| FY 2021 | 2021-12-31 | $7,776,000,000 | reported | |
| FY 2020 | 2020-12-31 | $6,675,000,000 | reported | |
| FY 2019 | 2019-12-31 | $6,260,000,000 | reported | |
| FY 2018 | 2018-12-31 | $5,825,000,000 | reported | |
| FY 2017 | 2017-12-31 | $5,307,000,000 | reported | |
| FY 2016 | 2016-12-31 | $4,888,000,000 | reported | |
| FY 2015 | 2015-12-31 | $4,765,000,000 | reported | |
| FY 2014 | 2014-12-31 | $4,785,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $3.24B | $3.24B | $2.03 | 422.13M sh | −5.7% | 141.7% |
| FY2024 | — | $1.86B | $1.86B | $1.80 | 447.79M sh | −2.2% | 80.9% |
| FY2023 | — | $1.09B | $1.09B | $1.56 | 457.87M sh | −1.2% | 67.4% |
| FY2022 | — | $1.59B | $1.59B | $1.35 | 463.39M sh | −1.8% | 120.2% |
| FY2021 | — | $743.00M | $743.00M | $1.08 | 471.97M sh | −0.7% | 42.8% |
Segments
LineFY2025ShareChange
United States Segment$5.10B54%+0.5%
International Segment$4.25B45%+3.7%
Total$9.47B
Pharmaceutical preparations
Zoetis Inc. is the 15th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
UPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—TEVATeva Pharmaceutical Industries Ltd$17.3B4.3%8.2%$50.9BREGNRegeneron Pharmaceuticals, Inc.$14.3B1.0%31.4%$96.0BVTRSViatris Inc$14.3B3.0%24.6%$23.7BVRTXVertex Pharmaceuticals Inc$12.0B8.9%32.9%$137.6BBHCBausch Health Companies Inc.$10.3B6.7%1.5%$3.1B
ZTSZoetis Inc. (this company)$9.5B2.3%28.2%$33.7B
OGNOrganon & Co.$6.2B2.9%3.0%$3.7BONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Zoetis Inc. · CIK 1555280 · Engraved from SEC EDGAR